Study evaluates drug-device combo therapy for deep vein thrombosis

A National Institutes of Health-sponsored study found that most patients with deep vein thrombosis should be treated with anticoagulant drugs alone, without a procedure-based intervention. However, the same study showed that a minimally-invasive catheter-director therapy, pharmacomechanical catheter-directed thrombolysis, provided greater initial pain relief and could prevent disability in DVT patients.

The research was presented today at the Society of Interventional Radiology‘s annual meeting. The Attract study compared the 2 treatment strategies for DVT in 692 patients and was supported by Boston Scientific (NYSE: BSX), BSN Medical, Medtronic (NYSE: MDT) and Genentech.

Get the full story at our sister site, Drug Delivery Business News.

The post Study evaluates drug-device combo therapy for deep vein thrombosis appeared first on MassDevice.

from MassDevice http://ift.tt/2mO3Tfl